Mycamine and Hepatitis - a phase IV clinical study of FDA data

Summary:

Hepatitis is reported as a side effect among people who take Mycamine (micafungin sodium), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Methotrexate, and have Fever.

The phase IV clinical study analyzes which people have Hepatitis when taking Mycamine. It is created by eHealthMe based on reports of 2,229 people who have side effects when taking Mycamine from the FDA, and is updated regularly.

What is Mycamine?

Mycamine has active ingredients of micafungin sodium. eHealthMe is studying from 2,237 Mycamine users. Check the latest studies of Mycamine.

What is Hepatitis?

Hepatitis (inflammation of the liver) is found to be associated with 1,462 drugs and 1,522 conditions by eHealthMe. Check the latest studies of Hepatitis.

On Jul, 18, 2026

2,229 people reported to have side effects when taking Mycamine.
Among them, 13 people (0.58%) have Hepatitis.

Among these 13 people:

How long have people been on Mycamine when they have Hepatitis? *

What is the gender of people who have Hepatitis when taking Mycamine? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Hepatitis when taking Mycamine? *

What are other drugs people take besides Mycamine? *

What are other side effects people have besides Hepatitis? *

Febrile Bone Marrow Aplasia (bone marrow greatly decreases or stops production of blood cells): 2 people, 15.38%
Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 2 people, 15.38%
Blood Bilirubin Increased: 2 people, 15.38%
Aplasia (defective development or congenital absence of an organ or tissue): 2 people, 15.38%
Rashes (redness): 1 person, 7.69%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 1 person, 7.69%
Nausea And Vomiting: 1 person, 7.69%
Febrile Neutropenia (fever with reduced white blood cells): 1 person, 7.69%

What are the existing conditions these people have? *

Fever: 4 people, 30.77%
Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi): 2 people, 15.38%
Post Procedural Infection: 2 people, 15.38%
Pain: 2 people, 15.38%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 15.38%
Aplastic Anemia: 2 people, 15.38%
B-Cell Type Acute Leukaemia (cancer of the white blood cells): 2 people, 15.38%
Acute Lymphocytic Leukaemia (In Remission): 1 person, 7.69%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 1 person, 7.69%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Mycamine and have Hepatitis?

- Check whether Hepatitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mycamine:

Mycamine (2,237 reports)

Hepatitis treatments and more:

Hepatitis (31,197 reports)

Browse all side effects of Mycamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis:

Hepatitis (1,463 drugs)

Browse all the conditions that are associated with Hepatitis:

Hepatitis (1,522 conditions)

Related publications that referenced our studies

Mati?, K., & Pele?, A. M. , "Drug-induced toxic hepatitis associated with the combination of quetiapine and fluphenazine: A case report", The European Journal of Psychiatry, 2018 Jan .
Cheng HI, Chen TH, Chung TC, Lee HY, Yu CY, "Micafungin-Induced Hyperbilirubinemia: A Case Report", 臺灣臨床藥學雜誌, 2014 Jun .
Mati?, K., & Pele?, A. M. , "Drug-induced toxic hepatitis associated with the combination of quetiapine and fluphenazine: A case report", The European Journal of Psychiatry, 2018 Jan .
Cheng HI, Chen TH, Chung TC, Lee HY, Yu CY, "Micafungin-Induced Hyperbilirubinemia: A Case Report", 臺灣臨床藥學雜誌, 2014 Jun .

How the study uses the data?

The study uses data from the FDA. It is based on micafungin sodium (the active ingredients of Mycamine) and Mycamine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.